KC7F2

  Cat. No.:  DC8447   Featured
KC7F2
Chemical Structure
927822-86-4
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
KC7F2 is a potent HIF-1 pathway inhibitor and that its potential as a cancer therapy agent warrants further study.
Cas No.: 927822-86-4
Chemical Name:
Synonyms:
SMILES: C1=CC(=C(C=C1Cl)S(=O)(=O)NCCSSCCNS(=O)(=O)C2=C(C=CC(=C2)Cl)Cl)Cl
Formula: C16H16Cl4N2O4S4
M.Wt: 570.38
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:
Description: KC7F2 is a potent HIF-1 pathway inhibitor and that its potential as a cancer therapy agent warrants further study. KC7F2 is the second HIF-1α inhibitor. KC7F2 is shown to inhibit the proliferation of cancer cells, an effect that is increased in hypoxia, while non-tumor cells are less sensitive. KC7F2 decreases HIF-1α levels by downregulating HIF-1α protein synthesis. KC7F2 markedly inhibits HIF-mediated transcription in cells derived from different tumor types, including glioma, breast and prostate cancers and exhibited enhanced cytotoxicity under hypoxia. KC7F2 prevents the activation of HIF-target genes such as Carbonic Anhydrase IX, Matrix Metalloproteinase 2 (MMP2), Endothelin 1 and Enolase 1. KC7F2 works through the down-regulation of HIF-1α protein synthesis, an effect accompanied by the suppression of the phosphorylation of eukaryotic translation initiation factor 4E binding protein 1 (4EBP1) and p70 S6 kinase (S6K), key regulators of HIF-1α protein synthesis. For the detailed information of KC7F2, the solubility of KC7F2 in water, the solubility of KC7F2 in DMSO, the solubility of KC7F2 in PBS buffer, the animal experiment (test) of KC7F2, the cell expriment (test) of KC7F2, the in vivo, in vitro and clinical trial test of KC7F2, the EC50, IC50,and affinity,of KC7F2, For the detailed information of KC7F2, the solubility of KC7F2 in water, the solubility of KC7F2 in DMSO, the solubility of KC7F2 in PBS buffer, the animal experiment (test) of KC7F2, the cell expriment (test) of KC7F2, the in vivo, in vitro and clinical trial test of KC7F2, the EC50, IC50,and affinity,of KC7F2, Please contact DC Chemicals.
In Vivo:
In Vitro:
References:
Kinase Assay:
Cell Assay:
Animal Administration:
References:
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC9811 PT2399 PT2399(PT=2399) is a novel HIF2α Antagonist.
DC12043 KHS-101 KHS101 is a selective inducer of neuronal differentiation; induces neuronal differentiation in cultured hippocampal neural progenitor cells (NPCs) by interacting with TACC3 (EC50 ~1 μM).
DC8447 KC7F2 KC7F2 is a potent HIF-1 pathway inhibitor and that its potential as a cancer therapy agent warrants further study.
DC8617 JNJ-42041935 JNJ-42041935 is a potent (pKi = 7.3-7.9), 2-oxoglutarate competitive, reversible, and selective inhibitor of PHD enzymes.
DC10825 IOX4 IOX4 is a potent inhibitor of PHD2 (IC50 = 1.6 nM).
DC8195 FG2216 FG-2216 is a potent HIF-prolyl hydroxylase inhibitor with IC50 of 3.9 uM for PDH2 enzyme; orally bioavailable and induced significant and reversible Epo induction in vivo.
DC11402 Desidustat Desidustat is an inhibitor of HIF hydroxylase.